Acute Onset Neurological Disorders during Pregnancy: A Literature Review

Doenças neurológicas de início durante a gravidez: análise crítica da literatura

Zita Ferraz1 Joana Parra2 Ana Luísa Areia1,3 Elsa Vasco1 Paulo Moura1,3

1 Obstetrics Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
2 Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
3 Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal

Abstract

Objectives To characterize the most common peripheral and central neurological disorders during pregnancy.

Methods Original research and review of the literature on neurological complications during pregnancy. We searched for keywords related to the topic on different databases.

Results Pregnancy involves physiological changes that can trigger peripheral neurological and/or central nervous system pathologies, which can sometimes be associated with hypertensive disorders. A definitive diagnosis of neurological disorders can be made according to the trimester of pregnancy and the clinical findings. Carpal tunnel syndrome and peripheral facial palsy are common peripheral neurological disorders, more frequent in the second half of pregnancy. Central nervous disorders are more complex and a precise diagnosis must be made in order to improve perinatal outcomes, provide correct management and treatment and to prevent acute and long-term complications.

Conclusions It is possible to achieve a precise diagnosis, management and treatment of neurological disorders during pregnancy, but these require a multidisciplinary approach, crucial to improve perinatal outcomes.

Resumo

Objetivos Caracterizar as alterações neurológicas centrais e periféricas mais comuns durante a gravidez.

Métodos Foi efetuada uma revisão da literatura acerca de complicações neurológicas durante a gravidez. Foram utilizadas diversas bases de dados usando palavras-chave relacionadas com o tema.

Resultados A gravidez envolve alterações fisiológicas que podem desencadear alterações neurológicas periféricas e/ou do sistema nervoso central, por vezes associadas a distúrbios hipertensivos. Um diagnóstico definitivo pode ser feito tendo...
Introduction

Pregnancy is associated with anatomical and physiological changes, such as decreased vascular resistance, increased vascular permeability and cardiac output. These are essential to accommodate plasma volume expansion and guarantee perfusion of vital organs. Nevertheless, fluctuations in estrogen concentration can increase coagulation factors and lead, consequently, to an increased risk of thromboembolism. In these situations, elevated levels of progesterone induce vasodilation, vascular stasis and edema, which further increase the risk of thromboembolism.

The risk of hypertension caused by the higher resistance in maternal systemic blood vessels, which occurs in cases of preeclampsia, can adversely affect blood flow in many organs (including liver, kidneys, brain and placenta). Thus, women with preeclampsia and eclampsia have an increased risk of complications, such as pulmonary edema, placental abruption, aspiration pneumonia, renal failure, hepatic failure and stroke.

Some peripheral neuropathies (carpal tunnel syndrome, peripheral facial palsy) and some central neurological disorders (seizure, migraine, cerebrovascular malformations, epilepsy) may be more frequent during pregnancy due to an exacerbation of a preexisting neurological condition, or by an acute onset of a neurological disorder associated with physiological changes engendered by pregnancy (such as headache or vascular disorders).

Both peripheral and central neurological disorders can occur during the three trimesters of pregnancy. So, an early and accurate diagnosis is essential to improve pregnancy management, treatment and subsequent perinatal outcomes.

The aim of this review is to describe and characterize the most common peripheral and central neurological disorders during pregnancy and subsequent management and treatment thereof.

Methods

A systematic search was conducted using Medline, PubMed, MeSH and ScienceDirect. Combinations of the search terms “pregnancy,” “carpal tunnel syndrome,” “Bell’s palsy,” “headache,” “cerebral thrombosis,” “cerebral hemorrhage,” “diagnosis,” “management” and “treatment” were used. A total of 76 articles were included in this review, published between 2005 and 2017.

Results

Both peripheral and central neurological disorders can occur during the three trimesters of pregnancy and arise from specific changes occurring in each trimester (Table 1).

Peripheral Neurological Disorders

Carpal tunnel syndrome and peripheral facial palsy are common examples of minor peripheral neurological disorders in pregnancy. However, factors that predispose to neuropathies should be considered in pregnant women, including diabetes, thyroid disorders, and/or inherent neuropathies (Charcot-Marie-Tooth disease).

Although most neuropathies are usually reversible, associated disabilities or morbidities can limit function and require therapy.

Carpal tunnel syndrome is a group of symptoms caused by compression of the median nerve in the carpal tunnel, characterized by numbness, tingling and weakness in the thumb, index, middle, half of the ring finger and parts of the palm of the hand (supplied by the median nerve). The incidence varies from 2 to 70% during pregnancy depending on the diagnostic method and the physician.

Complaints occur most commonly in the second and third trimester (Table 1), in the morning and at night. They are associated with venous congestion and/or nerve compression upon wrist flexion during sleep. Hormonal changes, fluid accumulation with a predisposition to edema, nerve hypersensitivity and glucose level fluctuations can all increase the risk of pregnant women developing symptoms of carpal tunnel syndrome. Diagnosis is clinical and could be confirmed by electrodiagnostic testing.

Conservative treatment is almost always appropriate and a complete recovery after pregnancy is the rule. In cases requiring intervention, first-line treatment includes overnight immobilization of the wrist with a splint in a neutral position or in slight extension. If necessary, local procedures such as an intracarpal steroid injection and surgery (with local anesthesia) are safe for mother and fetus.
Peripheral Disorders | First trimester | Second trimester | Third trimester | Comments
---|---|---|---|---
Carpal Tunnel Syndrome | + | ++ | +++ | Pregnant women: - shorter duration of symptoms - ↓ incidence in both hands - weaker intensity of symptoms
Bell’s palsy | + | + | +++ | Rarely recurrent

Central Disorders

Headache

| | a) without aura | b) with aura |
---|---|---|---|---
MH | +++ | ++ | +/+ | - MH is as a possible predictor of complications in pregnancy (miscarriage, preeclampsia, eclampsia, CVT, stroke, low birth weight)↓ - Inconsistent by deficient controlled studies

Cerebrovascular complications

- CVT | + | + | +++ | - AVM typically occurs earlier (15–20 weeks of GA) and in younger women (20–25 years-old)
- AVM | +++ | + | + | - Aneurysm rupture occurs later (30–40 weeks of GA) and in older women (30–35 years-old)
- Aneurysm rupture | + | ++ | +++ | - SAH occurs commonly as a result of ruptured aneurysm
- SAH | (see comments) | (see comments) | (see comments) | (see comments)

Abbreviations: AVM, arterial-venous malformation; CVT, cerebral vein thrombosis; GA, gestational age; MH, migraine headache; SAH, subarachnoid hemorrhage.

+ ↔ can occur; ++ ↔ common; +++ ↔ very common; - ↔ cessation; ± ↔ unchanged; ? ↔ unknown; Θ ↔ inexistent.

Peripheral facial palsy, also called Bell’s palsy, is an idiopathic facial neuropathy named after Sir Charles Bell, who first described this condition and its link to pregnancy. The incidence is around 28–45:100,000 pregnancies; it is rarely recurrent and it is more common in the third trimester (Table 1).8,9

The most frequent symptoms are unilateral weakness of the muscles controlling facial expressions (smiling, closing eyelids), dry eyes and mouth, hyperacusis to acute sounds and loss of taste over the anterior two thirds of the tongue ipsilateral to the facial weakness. It may be preceded or accompanied by ipsilateral retroauricular pain; some studies reveal that the increased incidence in pregnancy may be related to hypertensive disorders of pregnancy (preeclampsia, gestational hypertension).9,13,14

There are no specific treatments studied for peripheral facial palsy. The affected eye must be kept patched and moist to prevent corneal abrasions. Some neurologists prescribe a short course of steroids to minimize clinical features and increase the probability of facial nerve recovery.9,15

Central Neurological Disorders

Headache is a common presenting complaint during pregnancy.16,17 Despite the strong link between hormonal changes and headache, the recognition of non-hormonal factors is crucial. A pulsating and unilateral headache, associated with nausea and/or vomiting and/or photophobia or phonophobia are typical symptoms of a migraine headache (MH).1,5,18,19

About 8% of women suffering from MH experience an increase in the attack frequency and pain intensity of migraine during pregnancy, affecting more often those women with MH with aura.20 New-onset migraine arising during pregnancy usually takes place during the first trimester.1,5,20

If de novo MH occurs, it is more likely to occur with aura. In general, 50–75% of women with preexisting MH without aura see an improvement or complete remission during pregnancy. This fact suggests that high stable placental estrogen levels, mainly during the second and third trimesters of pregnancy, could be beneficial to this pathology.5,20,21

Studies have shown no difference in the incidence or course of MH between primiparous and multiparous women.1,21,22

The increase in estrogen levels can be the source of MH with aura in susceptible women. In general, women with MH (with or without aura) can be assured that there are no adverse effects on pregnancy’s outcome or maternal health. Nevertheless, some retrospective studies suggest that MH has been mentioned as a possible predictor of complications in pregnancy, including miscarriage, preeclampsia, eclampsia, congenital abnormalities, cerebral venous sinus thrombosis, stroke, and low birth weight; these links remain inconsistent due to poorly controlled studies.1,16,23

Imaging Studies

Neuroradiology is important to exclude secondary causes of headache. Imaging findings are usually normal in migraine. The indications for imaging testing are the same as those for non-pregnant women. The exclusion of threatening secondary causes is essential, especially if “red flags” are present (Fig. 1).

Magnetic resonance imaging (MRI) is safe during pregnancy; however, the use of gadolinium in pregnant women is...
controversial because it can cross the placenta (although it has not been shown to cause birth defects). Magnetic resonance imaging is recommended to assess the posterior fossa, while magnetic resonance arteriography (MRA) and magnetic resonance venography (MRV) are indicated to exclude vascular causes of headache.

Computed tomography (CT) scan without contrast is an imaging option in pregnancy in selected cases; however, the risk of in utero exposure to ionizing radiation limits its use.

When imaging studies are indicated, MRI should be used due to its higher resolution, increased sensitivity, and lack of ionizing radiation. The use of CT scan should be considered in selected cases, due to its wider availability and lower cost. Contrast agents should be avoided, unless absolutely necessary.

Symptomatic Treatment
Medical therapy should be selected taking into consideration adverse effects on the fetus. Symptomatic treatment during pregnancy is challenging and a detailed discussion of the risks and benefits of each medical treatment is essential (► Table 2).

First-line therapy includes an analgesic and an antiemetic drug. The pain management options for use during pregnancy described below are in accordance with the US Food and Drug Administration (FDA) recommendations.

**Analgesics**
Acetaminophen (category B for intravenous administration) is the analgesic of choice for short-term relief of mild to moderate pain during pregnancy, and it is considered a safe drug at therapeutic doses of ≤ 4 g per day for an adult. An analgesic dose of acetylsalicylic acid (100mg/day) is safe in the first and second trimesters, but it should be used with caution near term (category D) due to its effect on platelet function, causing an increased risk of prolonged labor, postpartum hemorrhage, neonatal bleeding and premature closure of the fetal ductus arteriosus. Metamizol/dipyrone (category C), by oral or intravenous route, has been demonstrated to be effective in the treatment of migraine attacks, but the risk of agranulocytosis, renal failure and hypotension limits its use.

**Non-Steroidal Antiinflammatory Drugs (NSAIDs)**
Studies do not satisfactorily support their use during pregnancy, except for ibuprofen (category C prior to 30 weeks and category D ≥ 30 weeks). Moreover, persistent exposure to NSAIDs, or any level of exposure to them after 30 weeks, is associated with an increased risk of premature closure of the ductus arteriosus and oligohydramnios due to its inhibitory effect on prostaglandin activity.

**Triptans**
In contrast to analgesics, the efficacy of triptans is due to the specifically targeted pathogenesis of MH. The safety of triptans during pregnancy is still questionable and their sustained use is discouraged unless no other treatment is successful. Sumatriptan and rizatriptan (category B) have not been associated with congenital abnormalities or adverse outcomes and, to date, the risk of major malformations has been reported to be equal to the baseline risk in the general population (1% to 3%).
Table 2 Symptomatic drugs used during pregnancy

<table>
<thead>
<tr>
<th>Drug</th>
<th>First Trimester</th>
<th>Second Trimester</th>
<th>Third Trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen/Paracetamol (≤ 4 g)</td>
<td>☺</td>
<td>☺</td>
<td>☺</td>
</tr>
<tr>
<td>Metamizol (Dipyrone)**</td>
<td>ID</td>
<td>ID</td>
<td>Avoid</td>
</tr>
<tr>
<td>Aspirin (≤ 100 mg/day)</td>
<td>(☼)</td>
<td>(☼)</td>
<td>Avoid</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diclofenac</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naproxen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>(☼)</td>
<td>(☼)</td>
<td>(☼)</td>
</tr>
<tr>
<td>Promethazine</td>
<td>(☼)</td>
<td>(☼)</td>
<td>(☼)</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>(☼)</td>
<td>(☼)</td>
<td>(☼)</td>
</tr>
<tr>
<td>Prochlorperazine*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisolone*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergotamine</td>
<td>CI</td>
<td>CI</td>
<td>CI</td>
</tr>
<tr>
<td>Almotriptan</td>
<td>ID</td>
<td>ID</td>
<td>ID</td>
</tr>
<tr>
<td>Eletriptan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frovatriptan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zolmitriptan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naratriptan</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Rizatriptan</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>

Abbreviations: CI, contraindicated; ID, insufficient data; ?, limited data, but probably safe.

ço, no evidence of harm; (☼) data suggest unlikely to cause harm.

*, for emergency treatment of migraine not responding to standard measure


Antiemetics
Metoclopramide (category B) is commonly used in pregnancy for its antiemetic and gastric prokinetic effects. Extrapyramidal reactions are the most common acute side effect of metoclopramide with a reported incidence of 0.2%. Promethazine (category C in the first trimester and B thereafter) and prochlorperazine (category C) are dopamine receptor antagonists and can be used combined with NSAIDs or opioids; the latter may be associated with congenital heart defects and cleft palate. Ondansetron (category B) should not be used as first-line treatment. Beginning the treatment after 10 weeks of gestational age (GA) minimizes the risks of teratogenicity.

Cerebrovascular disorders are uncommon in reproductive-aged women. Pregnancy-induced physiological changes increase the risk of cerebral venous thrombosis, as also do the existence of preeclampsia/eclampsia and thrombophilia.

Cerebral venous thrombosis
Most pregnancy-related cerebral venous thrombosis (CVT) occur in the third trimester of pregnancy and puerperium (Table 1), accounting for 27 to 57% of all pregnancy-related strokes. Common presenting complaints include headache (typically sub-acute), focal neurological deficits, seizures, altered mental status and signs of high intracranial pressure such as papilloedema. History of a previous extracerebral venous thrombotic event is also associated with adverse pregnancy outcomes and has a 3–4-fold higher risk of venous thrombotic event during subsequent pregnancies. Headache with focal neurological signs or seizures should raise the suspicion of CVT. Diagnosis is based on neuroimaging, with MRI being preferable to CT scan because of its higher resolution, sensitivity, and lack of ionizing radiation. In most cases, CT results will show nonspecific edema or infarction. Fetal outcomes after a CVT seem to be favorable and have low mortality rates.

Anticoagulation during pregnancy must be individualized according to the co-existence of risk factors. Evidence suggests the use of maintenance anticoagulation for a period of 3 months in presence of high risk factors, and for at least 6–12 months in patients with idiopathic cases (potential etiologies include paroxysmal atrial fibrillation, patent foramen ovale, atherosclerotic plaques of the aortic arch, congenital and acquired prothrombotic states) and women with mild hereditary thrombophilia (heterozygous factor V Leiden or prothrombin G20210A mutation). Indefinite anticoagulation should be reserved to patients with idiopathic cases, recurrent episodes, and to those with high-risk thrombophilia (antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation, antiphospholipid antibodies and combined abnormalities).

Hemorrhagic disorders
Bleeding of an arteriovenous malformation (AVM) is a cerebrovascular complication that is noticeable in younger women (20–25 years-old) and earlier in pregnancy (15–20 weeks after conception).
of GA); in contrast, aneurysm rupture occurs more common-
ly in older women (30–35 years-old) and between 30–40
weeks of GA.5,26 Possible mechanisms include hormonal
changes (that lead to a predisposition to the development,
enlargement and rupture of an aneurysm), increase in
heart output by 60% in the second trimester and higher
blood volume in the third trimester, which all increase the
risk of aneurysm rupture. Women generally present with
an abrupt onset of a severe and unusual headache (thunderclap
headache), nausea and vomiting, photophobia, syncope and
focal neurological deficits. If brain CT without contrast does
not provide a diagnosis, a lumbar puncture should be per-
formed.57 For hemorrhagic AVM, cerebral angiography is
necessary. An unruptured AVM in pregnancy, with no bleed-
ing risk factors (aneurysm, venous ectasia), should be fol-
lowed conservatively.6,56,58 In contrast, an emergency
surgery is necessary for a bleeding cerebral AVM, particularly
if the existence of a hematoma causes worsening of neuro-
logical symptoms or cerebral herniation.14,56,58

Endovascular embolization for cerebral AVM in pregnancy
should be performed per clinical manifestations and angio-
graphic features. Several studies reported that this proce-
dure during pregnancy is safe and effective.56,59,60 The
radiation dose of endovascular and stereotactic radiotherapy
during pregnancy is also safe.16 However, non-radiation
procedures are preferred during pregnancy. In cases of
unruptured AVM, vaginal delivery or caesarean section
should depend on obstetric criteria.56,61

Subarachnoid hemorrhage (SAH) occurs most commonly
because of ruptured aneurysm or AVM. The frequency of SAH
in pregnancy is 5.8:100,000 deliveries in the United States of
America.62 The most common symptom is severe headache.
Computed tomography scan is the diagnostic exam of choice
as it can identify hyperdense signal provided by the extrava-
sated blood in the basal cisterns.24,57 It is unclear whether
the risk of SAH is increased during pregnancy and the
puerperium and there are no formal studies to support
optimal obstetric management of pregnant women with
SAH. Mode of delivery is based solely on obstetric
criteria.58,61–63

Discussion

Pregnancy is associated with a risk of thromboembolism and
can lead to neurological disorders. So, women who present
with acute neurological symptoms require a meticulous
diagnostic evaluation.1–3,64 Carpal tunnel syndrome and
peripheral facial palsy are common examples of peripheral
neurological disorders, which occur more often in the third
trimester due to physiologic changes during pregnancy.7,10,11,65,66
Generally, surgery is not required and medical
treatment is satisfactory.10,11,65 However, some women can
maintain symptoms in the first three years post-partum.10,12

Central nervous system disorders are more complex. The
acknowledgment of symptoms and imaging testing, if nec-
essary, are extremely important to attain the correct diagno-
sis. Magnetic resonance imaging is safe during pregnancy
and CT scan should be avoided and used only if absolutely
necessary.16,21 Both diagnosis and management of headache
in pregnant women present several challenges. Migraine is
the most common and well-studied type of headache and it
is divided in two main subtypes: with aura, occurring
predominantly in the third trimester; and without aura,
most common in the first trimester, improving in the third
trimester.1,5,20 In contrast, ~ 8% of women experience
increased frequency or intensity of MH during pregnancy.5
Data showed no difference in the incidence or course of MH
between primiparous and multiparous women.1,21,22 Sympt-
omatic treatment during pregnancy is challenging and
should be selected taking into consideration adverse effects
on the fetus. The literature is consensual that analgesic (such
as acetaminophen) and antiemetic drugs (such as metoclo-
pramide) are the first-line therapy of choice.25,27 Recently,
a preliminary study with recommended doses of acetamino-
phen was performed to investigate the potential effect of
perinatal exposure on metabolic function in mice offspring.
The authors concluded that acetaminophen may be associ-
ated with impaired glucose metabolism, increased plasma
insulin level, and reduced liver glycogen content; however,
future investigation is warranted to demonstrated this
potential association.63 Generally, acetaminophen is consid-
ered a safe drug at therapeutic doses. However, acetamino-
phen overdose remains the most common cause of acute
liver failure in the western world,68 and women must be
warned that safe dosage needs to be respected. Some triptans
(sumatriptan and rizatriptan) can be used, although their
safety in pregnancy remains unknown.25,29,36 Non-steroidal
anti-inflammatory drugs should be avoided mainly in the
third trimester due to its association with premature closure
of the foetal ductus arteriosus, oligohydramnios and risk of
postpartum hemorrhage.25,34,35 For all these facts, medical
treatment has to be conscientious, maintaining doses as low
as possible, individualized to each woman. The prognosis of
migraine (with or without aura) is favorable and literature
does not provide evidence of complications.5,20 Neverthe-
less, perinatal adverse outcomes can occur in women with no
evidence of remission or amelioration of migraine at-
tacks.69,70 So, MH should be considered a potential risk
factor in obstetric care and has to be managed by a multidis-
ciplinary team.

Cerebral venous thrombosis frequently occurs during the
third trimester and puerperium.44,49–51 The literature is not
consensual about the risk of recurrence of CVT. Generally,
fetal outcome of a pregnancy after a CVT seems to be
favorable.43–45,47 The risk of stroke is elevated during the
first year postpartum, lowering in subsequent years.71 How-
ever, history of a previous extracerebral venous thrombotic
event is associated with adverse pregnancy outcome and has
a 3–16-fold higher risk of venous thrombotic event during
subsequent pregnancies.44,72 Cerebral venous thrombosis
recurrence is 80-fold higher than the baseline risk described
in general population studies.72 Mehraein et al73 studied the
outcomes of 21 pregnancies with a previously treated CVT.
Low-dose heparin was given subcutaneously during the
course of 5 of these pregnancies, while no anticoagulation
was given during the course of the remaining 14 pregnancies
and puerperium periods. None of patients had recurrence of CVT during pregnancy and puerperium and no extracerebral vascular thromboembolism occurred. They concluded that a history of CVT does not justify a negative advice on pregnancy in women. Current guidelines of the Royal College of Obstetricians and Gynaecologists for the prevention of thromboembolism defend that all women should undergo a documented assessment of risk factors in early pregnancy or pre-pregnancy and risk assessment should be repeated intrapartum or immediately postpartum. Women with a previous episode of thromboembolism (associated with antithrombin deficiency or with recurrent episodes of thromboembolism) should be offered thromboprophylaxis with a higher dose of anticoagulant therapy antenatally and for 6 weeks postpartum (or until returned to oral anticoagulant therapy after delivery). Instead, women in whom the original episode of thromboembolism was unprovoked/idiopathic or related to estrogen (for instance, in pregnancy) should be offered thromboprophylaxis with anticoagulant therapy throughout the antenatal period. In terms of the peripartum period, a recent integrated analysis of two prospective studies concluded that antithrombin concentrate is safe and effective in reducing venous thromboembolism if administered over an average period of 4 days. As so, more studies are warranted to define the real risk of thromboembolism in subsequent pregnancies and anticoagulation therapy to prevent complications and risk of recurrence in future pregnancies; the risk of thromboembolism should be discussed with women at risk and the reasons for individual recommendations explained.

Arteriovenous malformation complications are more frequent in the first trimester, contrasting to aneurysm rupture, which occurs more commonly in the second half of pregnancy. Both can lead to SAH. It is consensual that imaging investigation is vital and, during pregnancy, MRI is preferable to CT scan because of its higher resolution, sensitivity, and lack of ionizing radiation. In addition, MRV and MRA can be performed for the exclusion of vascular disorders and contrast agents cause adverse fetal effects and should avoided, unless absolutely necessary for an accurate diagnosis.

Data are consistent that the appropriate delivery in cases of neurological complications remains undefined and the decision of the way should be based on obstetric criteria if the hemorrhagic risk has been removed. After appropriate diagnosis, proper treatment and follow-up are extremely important. In cases of cerebrovascular complications, the management and follow-up by a multidisciplinary team is mandatory. With scientific advances, the ability to diagnose and discriminate different causes of acute neurological symptoms is likely to progress. Because most of these conditions are rare, an early transfer to a Reference Centre and a multidisciplinary approach is essential to improve maternal and fetal outcomes.

Conclusions

Pregnancy is characterized by anatomic and physiologic changes that can trigger or potentiate neurological complaints. According to the pregnancy trimester, clinical findings, maternal age and risk factors, a definitive diagnosis of central or peripheral neurological disorders can be made, with appropriate management. An adequate treatment and supervision of these conditions are extremely important, with a multidisciplinary approach being essential to improve outcomes and prevent acute and long-term complications.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare they have no conflict of interest.

References


